NO940660L - HLA - begrensete Hepatit B virus CTL-epitoper - Google Patents

HLA - begrensete Hepatit B virus CTL-epitoper

Info

Publication number
NO940660L
NO940660L NO940660A NO940660A NO940660L NO 940660 L NO940660 L NO 940660L NO 940660 A NO940660 A NO 940660A NO 940660 A NO940660 A NO 940660A NO 940660 L NO940660 L NO 940660L
Authority
NO
Norway
Prior art keywords
hbv
peptides
hla
restricted
hepatitis
Prior art date
Application number
NO940660A
Other languages
English (en)
Other versions
NO940660D0 (no
Inventor
Maria A Vitiello
Robert W Chesnut
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of NO940660D0 publication Critical patent/NO940660D0/no
Publication of NO940660L publication Critical patent/NO940660L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cytotoksiske T-lymfocyttstimuierende peptider induserer HLA-begrensede responser på hepatitt B virus antigener. Peptidene, avledet fra CTL-epitopregioner av både HBV-overfla- te- og nukleokapsidantigener, er særlig nyttige ved behandling og forebyggelse av HBV-infeksjon, innbefattet behandling av kronisk infiserte HBV-bærere. Peptidene kan formuleres som HBV-vaksiner og farmasøytiske blandinger, såsom lipidholdige blandinger for å øke de HLA-begrensede CTL-responser. Pepti- dene er også nyttige i diagnostiske metoder, slik som å forut- si hvilke HBV-infiserte individer som er tilbøyelige til å utvikle kronisk infeksjon.
NO940660A 1991-08-26 1994-02-25 HLA - begrensete Hepatit B virus CTL-epitoper NO940660L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74956891A 1991-08-26 1991-08-26
US82768292A 1992-01-29 1992-01-29
US87449192A 1992-04-27 1992-04-27
PCT/US1992/007218 WO1993003764A1 (en) 1991-08-26 1992-08-26 Hla-restricted hepatitis b virus ctl epitopes

Publications (2)

Publication Number Publication Date
NO940660D0 NO940660D0 (no) 1994-02-25
NO940660L true NO940660L (no) 1994-04-22

Family

ID=27419385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940660A NO940660L (no) 1991-08-26 1994-02-25 HLA - begrensete Hepatit B virus CTL-epitoper

Country Status (16)

Country Link
EP (2) EP0534615B1 (no)
JP (2) JP3738395B2 (no)
AU (1) AU687725B2 (no)
BG (1) BG98523A (no)
CA (1) CA2115839C (no)
CZ (1) CZ42794A3 (no)
DE (1) DE69231621T2 (no)
ES (1) ES2155060T3 (no)
FI (1) FI940918A7 (no)
GR (1) GR3035575T3 (no)
HU (1) HUT68510A (no)
IL (1) IL102964A0 (no)
NO (1) NO940660L (no)
NZ (2) NZ270605A (no)
OA (1) OA09888A (no)
WO (1) WO1993003764A1 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
WO1994025060A1 (en) * 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
DE69435171D1 (de) 1993-09-14 2009-01-08 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
JP2001508054A (ja) * 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
CN1216900C (zh) * 1997-04-11 2005-08-31 桑斯塔特医学有限公司 用于调节免疫系统活性和抑制炎症的细胞调节性亲脂肽
RU2116086C1 (ru) * 1997-08-19 1998-07-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Способ вакцинации против вирусного гепатита b
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
EP1230268B1 (en) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
JP2008501640A (ja) * 2004-04-21 2008-01-24 ザ ユニヴァーシティー オヴ シカゴ ミオシン軽鎖キナーゼ阻害剤及びその使用
AU2007284656A1 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
KR101543622B1 (ko) 2006-10-17 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2276495B1 (en) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
RU2555346C2 (ru) 2009-08-07 2015-07-10 Трансген Са Композиция для лечения инфекции вирусом гепатита в
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
JP5564730B2 (ja) 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
WO2013036201A1 (en) * 2011-09-06 2013-03-14 Agency For Science, Technology And Research Polypeptide vaccine
CA2876656C (en) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
CN113144188A (zh) 2012-09-21 2021-07-23 Pds生物科技公司 改进的疫苗组合物和使用方法
CN103961306A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 经皮给予用疫苗组合物
CN103961697A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
CA2994929A1 (en) 2015-08-12 2017-02-16 Oncotherapy Science, Inc. Depdc1-derived peptide and vaccine containing same
HK1255206A1 (zh) * 2015-09-08 2019-08-09 苏黎世大学 抗猫过敏的组合物
SG11201802286PA (en) 2015-10-08 2018-04-27 Oncotherapy Science Inc Mphosph1-derived peptide, and vaccine including same
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2019113200A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
JPS60161999A (ja) * 1984-02-02 1985-08-23 Chemo Sero Therapeut Res Inst ペプチド
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
DE68924850T2 (de) * 1988-06-14 1996-10-10 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
EP0510054A1 (en) * 1990-01-05 1992-10-28 United Biomedical, Inc. Hiv-1 core protein fragments

Also Published As

Publication number Publication date
EP0534615B1 (en) 2001-01-03
BG98523A (en) 1995-05-31
HUT68510A (en) 1995-06-28
EP1018344A2 (en) 2000-07-12
CZ42794A3 (en) 1994-11-16
CA2115839C (en) 2010-06-01
IL102964A0 (en) 1993-01-31
DE69231621D1 (de) 2001-02-08
WO1993003764A1 (en) 1993-03-04
JP3586278B2 (ja) 2004-11-10
FI940918L (fi) 1994-04-08
HU9400581D0 (en) 1994-05-30
AU687725B2 (en) 1998-03-05
CA2115839A1 (en) 1993-03-04
JPH06510051A (ja) 1994-11-10
AU2548792A (en) 1993-03-16
FI940918A7 (fi) 1994-04-08
EP0534615A2 (en) 1993-03-31
OA09888A (en) 1994-09-15
FI940918A0 (fi) 1994-02-25
ES2155060T3 (es) 2001-05-01
NZ244103A (en) 1997-07-27
EP1018344A3 (en) 2000-09-20
NZ270605A (en) 1997-07-27
NO940660D0 (no) 1994-02-25
EP0534615A3 (en) 1994-05-25
JP3738395B2 (ja) 2006-01-25
DE69231621T2 (de) 2001-05-31
GR3035575T3 (en) 2001-06-29
JP2004075693A (ja) 2004-03-11

Similar Documents

Publication Publication Date Title
NO940660L (no) HLA - begrensete Hepatit B virus CTL-epitoper
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
DK0726758T3 (da) Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus
Wiktor Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
DE60024112D1 (de) Influenzavirus-impfstoffzusammensetzung
Cordero et al. Influenza vaccination in solid-organ transplant recipients
Maupas et al. Hepatitis B vaccine: efficacy in high-risk settings, a two-year study
DE69726734D1 (de) Menschliche monoklonale antikörper gegen das hepatitis b oberflächenantigen
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
PT625204E (pt) Terapeutica da hepatite
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
Hendrickx et al. Advances in hepatitis immunization (A, B, E): public health policy and novel vaccine delivery
RU93053037A (ru) Вакцина против заболевания сумки птиц и способы лечения
Alonso et al. Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report
DE60229126D1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
Charney et al. Immunization studies with mammary tumor virus
EP0591384A4 (en) ATTENUATED RE-MUTURED VIRUS VACCINE AGAINST MAREKS DISEASE SEROTYPE-1.
RU2006117308A (ru) Фармацевтические композиции для терапевтического применения
Miller Reader'Forum
Park et al. Heat-inactivated and Aggregated HBsAg as a New Type of Vaccine Against Hepatitis B
Shouval Adoptive immune transfer as a therapeutic approach for persistent hepatitis B virus infection
RU94032103A (ru) Пептиды, фармацевтическая композиция, вакцина, конъюгат, способы лечения и идентификации